Wang Y et al.Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.Oncol Lett 13:1165-1174 (2017).
Liu W et al.Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues.Int J Endocrinol 2017:9606985 (2017).
Hasegawa K et al.Somatostatin receptor staining in FFPE sections using a ligand derivative dye as an alternative to immunostaining.PLoS One 12:e0172030 (2017).
Sizdahkhani S et al.Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.Sci Rep 7:40822 (2017).
Iacovazzo D et al.Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.Eur J Endocrinol 174:241-50 (2016).
Pivonello C et al.Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.Endocrine N/A:N/A (2016).
Lehmann A et al.Carboxyl-terminal receptor domains control the differential dephosphorylation of somatostatin receptors by protein phosphatase 1 isoforms.PLoS One 9:e91526 (2014).
Sadowski SM et al.Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report.Gland Surg 3:E1-5 (2014).
Clifton-Bligh RJ et al.Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.J Clin Endocrinol Metab 98:687-94 (2013).
Chinezu L et al.Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies.Hum Pathol N/A:N/A (2013).